• Home
  • NEW DAY MEDICINE
  • 12 (86) 2025
  • 34 -12 (86) 2025 - Safarova D.Z. - CURRENT CHALLENGES IN GYNECOLOGIC ONCOLOGY: INSUFFICIENT COVERAGE OF CERVICAL CANCER SCREENING AND HPV VACCINATION

34 -12 (86) 2025 - Safarova D.Z. - CURRENT CHALLENGES IN GYNECOLOGIC ONCOLOGY: INSUFFICIENT COVERAGE OF CERVICAL CANCER SCREENING AND HPV VACCINATION

CURRENT CHALLENGES IN GYNECOLOGIC ONCOLOGY: INSUFFICIENT COVERAGE OF CERVICAL CANCER SCREENING AND HPV VACCINATION

Safarova D.Z. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Cervical cancer remains one of the most preventable malignancies in women, yet it continues to cause significant morbidity and mortality worldwide. Despite the availability of effective screening methods and prophylactic HPV vaccines, many low- and middle-income countries still suffer from inadequate program coverage. This review highlights the main barriers to widespread implementation of screening and vaccination programs and emphasizes the need for integrated public health strategies to reduce the global burden of cervical cancer.

Key words: cervical cancer, HPV vaccination, screening coverage, gynecologic oncology, prevention barriers, public health, epidemiology.

First page

200

Last page

202

For citation:Safarova D.Z. - CURRENT CHALLENGES IN GYNECOLOGIC ONCOLOGY: INSUFFICIENT COVERAGE OF CERVICAL CANCER SCREENING AND HPV VACCINATION//New Day in Medicine 12(86)2025 200-202 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

  1. Banerjee S., Kaye, S. B. (2021). PARP inhibitors in ovarian cancer: An evolving landscape. // Nature Reviews Clinical Oncology, 2021;18(6):422-439.
  2. Makker V., Rasco, D., Vogelzang, N. J., et al. (2020). Lenvatinib plus pembrolizumab in advanced endometrial cancer. The New England Journal of Medicine, 2020;383(1):23-34.
  3. Colombo, N., Sessa, C., du Bois, A., et al. (2022). ESMO guidelines for the management of gynecological malignancies. Annals of Oncology, 2022;33(1):42-56.
  4. Perren, T. J., Swart, A. M., Pignata, S., et al. (2021). A phase III trial of bevacizumab in ovarian cancer. The Lancet Oncology, 2021;22(5):657-669.
  5. Monk, B. J., Willmott, L. J., Sumner, D. A. (2020). Anti-PD-1 and PD-L1 therapy in cervical cancer. Gynecologic Oncology, 2020;158(1):167-175.
  6. Nezhat, C., Kennedy-Benson, A., Rahaman, J. (2022). Advances in minimally invasive surgery for gynecologic cancers. Journal of Minimally Invasive Gynecology, 2022;29(3):309-318.
  7. Isakovna, K. D. (2024). Diagnosis and prognosis of liver fibrosis in chronic viral hepatitis c in hiv-infected children. Journal of healthcare and life-science research 2024;3(5):127-133.
  8. Ibrokhimovna M. M. (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. Journal of Intellectual Property and Human Rights, 2024;3(4):19–25. Retrieved from http://journals.academiczone.net/index.php/jiphr/article/view/2506

    file

    download